BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 31280356)

  • 1. Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation.
    Matusik PT; Małecka B; Lelakowski J; Undas A
    Clin Res Cardiol; 2020 Apr; 109(4):426-434. PubMed ID: 31280356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated NT-proBNP is associated with unfavorably altered plasma fibrin clot properties in atrial fibrillation.
    Matusik PT; Matusik PS; Kornacewicz-Jach Z; Małecka B; Ząbek A; Undas A
    Int J Cardiol; 2017 Sep; 243():244-250. PubMed ID: 28571619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.
    Santema BT; Chan MMY; Tromp J; Dokter M; van der Wal HH; Emmens JE; Takens J; Samani NJ; Ng LL; Lang CC; van der Meer P; Ter Maaten JM; Damman K; Dickstein K; Cleland JG; Zannad F; Anker SD; Metra M; van der Harst P; de Boer RA; van Veldhuisen DJ; Rienstra M; Lam CSP; Voors AA
    Clin Res Cardiol; 2020 Mar; 109(3):331-338. PubMed ID: 31263996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prothrombotic State in Atrial Fibrillation Patients With One Additional Risk Factor of the CHA
    Głowicki B; Matusik PT; Plens K; Undas A
    Can J Cardiol; 2019 May; 35(5):634-643. PubMed ID: 30955928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NT-proBNP is a powerful predictor for incident atrial fibrillation - Validation of a multimarker approach.
    Svennberg E; Lindahl B; Berglund L; Eggers KM; Venge P; Zethelius B; Rosenqvist M; Lind L; Hijazi Z
    Int J Cardiol; 2016 Nov; 223():74-81. PubMed ID: 27541645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supraventricular arrhythmia, N-terminal pro-brain natriuretic peptide and troponin T concentration in relation to incidence of atrial fibrillation: a prospective cohort study.
    Xiao J; Persson AP; Engström G; Johnson LSB
    BMC Cardiovasc Disord; 2021 Mar; 21(1):134. PubMed ID: 33711943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-sensitivity troponin I in persistent atrial fibrillation - relation to NT-proBNP and markers of inflammation and haemostasis.
    Horjen AW; Ulimoen SR; Norseth J; Svendsen JH; Smith P; Arnesen H; Seljeflot I; Tveit A
    Scand J Clin Lab Invest; 2018 Sep; 78(5):386-392. PubMed ID: 29933716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation.
    Staszewsky L; Meessen JMTA; Novelli D; Wienhues-Thelen UH; Disertori M; Maggioni AP; Masson S; Tognoni G; Franzosi MG; Lucci D; Latini R
    BMC Cardiovasc Disord; 2021 Nov; 21(1):553. PubMed ID: 34798808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.
    Roldán V; Vílchez JA; Manzano-Fernández S; Jover E; Gálvez J; Puche CM; Valdés M; Vicente V; Lip GY; Marín F
    Stroke; 2014 Mar; 45(3):696-701. PubMed ID: 24519407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation.
    Drabik L; Wołkow P; Undas A
    Thromb Res; 2015 Aug; 136(2):408-14. PubMed ID: 26048399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.
    Khan SQ; Ng K; Dhillon O; Kelly D; Quinn P; Squire IB; Davies JE; Ng LL
    Eur Heart J; 2009 May; 30(9):1057-65. PubMed ID: 19168526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome.
    Lindholm D; James SK; Bertilsson M; Becker RC; Cannon CP; Giannitsis E; Harrington RA; Himmelmann A; Kontny F; Siegbahn A; Steg PG; Storey RF; Velders MA; Weaver WD; Wallentin L;
    Clin Chem; 2017 Feb; 63(2):573-584. PubMed ID: 27932413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional Diagnostic Value of Growth Differentiation Factor-15 (GDF-15) to N-Terminal B-Type Natriuretic Peptide (NT-proBNP) in Patients with Different Stages of Heart Failure.
    Li J; Cui Y; Huang A; Li Q; Jia W; Liu K; Qi X
    Med Sci Monit; 2018 Jul; 24():4992-4999. PubMed ID: 30019695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-Based Cardiac Biomarkers and the Risk of Cognitive Decline, Cerebrovascular Disease, and Clinical Events.
    Gyanwali B; Lai MKP; Lui B; Liew OW; Venketasubramanian N; Richards AM; Chen C; Hilal S
    Stroke; 2021 Jul; 52(7):2275-2283. PubMed ID: 33971742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SERUM cardiac-specific biomarkers and atrial fibrillation in myotonic dystrophy type I.
    Russo V; Rago A; Atripaldi L; Leonardi S; Papa AA; Politano L; Golino P; Potpara TS; Nigro G
    J Cardiovasc Electrophysiol; 2019 Dec; 30(12):2914-2919. PubMed ID: 31579995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes.
    Resl M; Clodi M; Vila G; Luger A; Neuhold S; Wurm R; Adlbrecht C; Strunk G; Fritzer-Szekeres M; Prager R; Pacher R; Hülsmann M
    Heart; 2016 Dec; 102(24):1963-1968. PubMed ID: 27456261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
    J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation.
    Svennberg E; Henriksson P; Engdahl J; Hijazi Z; Al-Khalili F; Friberg L; Frykman V
    Heart; 2017 Aug; 103(16):1271-1277. PubMed ID: 28255099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy.
    Hijazi Z; Oldgren J; Andersson U; Connolly SJ; Ezekowitz MD; Hohnloser SH; Reilly PA; Vinereanu D; Siegbahn A; Yusuf S; Wallentin L
    Circulation; 2012 Apr; 125(13):1605-16. PubMed ID: 22374183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
    Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
    Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.